Dravet Syndrome Treatment Market Size to grow by USD 727.9 million between 2024-2028
According to a research report “ Dravet Syndrome Treatment Market” by Product (SGDs, TGDs, FGDs) Distribution Channel (Hospital pharmacy, Retail pharmacy, E-commerce, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 727.9 million, at a CAGR of over 10.87% during the forecast period. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) employ distinct strategies to expedite the approval process for drugs targeting serious conditions, including Dravet Syndrome (DS). Orphan drug designations, fast-track designations, and breakthrough therapy designations facilitate the accelerated development and market entry of these treatments. For instance, Encoded Therapeutics Inc.'s lead asset, ETX101, received both orphan drug designation and rare pediatric disease designation from the FDA in May 2020 for DS treatment. In March 2021, the EU granted orphan drug approval to lorcaserin hydrochloride medication for DS treatment. These regulatory initiatives significantly reduce the time-to-market for life-saving therapies, ultimately benefiting patients and the healthcare industry.
Browse market data tables, figures, and in-depth TOC on “Dravet Syndrome Treatment Market” by Product (SGDs, TGDs, FGDs) Distribution Channel (Hospital pharmacy, Retail pharmacy, E-commerce, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Product, the SGDs segment is projected to dominate the market size in 2024
The Dravet Syndrome Treatment Market represents a significant business opportunity due to the high unmet medical need for effective therapies. This neurological disorder necessitates innovative solutions, and companies developing and marketing these treatments stand to gain substantial revenue growth. Key players in this market include Eisai, GW Pharmaceuticals, and Zogenix, who are currently leading the way with their FDA-approved therapies. The market's expansion is driven by increasing awareness, diagnostic advancements, and regulatory support for novel treatments.
By Distribution Channel, Hospital pharmacy segment is expected to hold the largest market size for the year 2024
The Dravet Syndrome Treatment Market represents a significant business opportunity due to the high unmet medical need for effective therapies. This neurological disorder necessitates innovative solutions to manage seizures and improve patient quality of life. Key market players are investing in research and development of novel treatments, including cannabidiol-based therapies and FDA-approved medications. The market is expected to grow substantially, driven by increasing disease awareness, regulatory approvals, and technological advancements.
North America is forecasted to hold the largest market size by region in 2024
The Dravet Syndrome Treatment Market represents a significant business opportunity due to the high unmet medical needs and the growing awareness and diagnosis rates of this severe and complex epilepsy condition. Key players in the market are focusing on developing and commercializing innovative therapies, including FDA-approved medications and novel treatments, to address the therapeutic challenges and improve patient outcomes. The market is expected to grow steadily due to increasing research and development investments and expanding patient populations.
The Dravet Syndrome Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Dravet Syndrome is a rare and severe form of epilepsy that begins in the first year of life and is characterized by frequent, prolonged seizures triggered by high fevers. This lifelong condition is caused by mutations in the SCN1A gene, which affects the function of the brain's sodium channels. The Dravet Syndrome treatment market has seen significant advancements in recent years, with several pharmaceutical companies, including Zogenix, conducting clinical trials for new therapies. Zogenix's drug application for tiripentol and topiramate, a combination therapy for Dravet Syndrome, is currently under review by the FDA. Adverse effects of the medication include gastrointestinal issues and sedation. Other therapies for Dravet Syndrome include Epidiolex, Clobazam, and Stiripentol. The medical industry is investing heavily in research and development for Dravet Syndrome, with the Dravet Foundation leading the way in advocacy and funding. Genetic testing is essential for an accurate diagnosis, and healthcare providers are working to streamline reimbursement procedures for these costly therapies. Infants and children with Dravet Syndrome require ongoing medication and monitoring for seizures and fevers, making access to effective treatments crucial. The future of Dravet Syndrome treatment holds promise, with ongoing clinical trials and advancements in our understanding of the condition.
Market Research Overview
Dravet Syndrome is a rare, lifelong neurological condition characterized by severe myoclonic seizures, often triggered by fever or high temperatures. Treatment options for Dravet Syndrome include various drugs such as benzodiazepines, anticonvulsants, and cannabinoids. Cannabidiol (CBD), a non-psychoactive component of cannabis, has shown promise in treating Dravet Syndrome through its interaction with the GABAergic regulatory element and the SCN1A gene. Pharmacies, including online and retail, play a crucial role in providing access to these medications. Product approvals and clinical trials are ongoing for various cannabinoid-based therapies, such as ETX101 from Encoded Therapeutics and fenfluramine medication from Epygenix Therapeutics. However, clinical hurdles and adverse effects, including feelings of depressive thoughts, nausea, impaired coordination, agitation, and drowsiness, remain challenges. Doctors and patients rely on a range of seizure medications, including valproate, stiripentol, and topiramate, as well as second-generation antiepileptic medications and vagus nerve stimulation. Treatment and management also involve diagnostic procedures like Electroencephalography (EEG) and magnetic resonance imaging (MRI). Pharmaceutical companies and healthcare providers are investing in research and development to address the unique needs of the Dravet syndrome child population. Reimbursement policies and procedures vary, with diagnostic laboratories and hospitals playing a role in SCN1A testing and medication access. The medical industry continues to explore alternative therapies, such as marijuana and its FDA-approved form, Epidiolex, as well as the ketogenic diet and surgical accessories. The Dravet Foundation and other organizations support ongoing research and advocacy efforts.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
